Nuvalent
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions activity mutant activity activity avoiding approved approved approved investigational activity i activity observed in patients with i i including after exhausting approved and investigational therapies such as and mutant activity observed in patients with resistance mutations activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events key observed in clinical investigation source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
29 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions activity mutant activity approved approved approved investigational activity i activity observed in patients with i i including after exhausting approved and investigational therapies such as and mutant activity activity observed in patients with resistance mutations activity key observed in clinical investigation activity avoiding patients activity observed in patients with history of metastases including intracranial responses in with emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions approved approved approved investigational by activity mutant activity activity key observed in clinical investigation activity observed in patients with including after exhausting approved and investigational therapies such as and activity observed in patients with resistance mutations activity mutant activity activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Investor Presentation
January 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions approved approved approved investigational by activity mutant activity activity key observed in clinical investigation activity observed in patients with including after exhausting approved and investigational therapies such as and activity observed in patients with resistance mutations activity mutant activity activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Related slides by other companies
Alkermes
Investor Day
March 2021
key differentiation parameters support broad potential utility validate molecular design demonstrate anti tumor activity create dosing flexibility support broad potential utility demonstrated selective expansion of and cells demonstrated minimal changes in peripheral regulatory cells in both intravenous and subcutaneous administrations single agent activity observed with combination activity observed in combination with anti both and in hard to treat tumors plans to progress into registration enabling studies only variant in development identified based on safety and anti tumor activity achieved first objective response activity observed with in experienced patients combination activity observed with combination activity observed with multiple agents in preclinical studies may offer dosing flexibility renal cell carcinoma recommended phase dose pharmacodynamic inhibitors net | Alkermes
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io